

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

September 23, 2025

To

BSE Limited

Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Outcome of Board Meeting – Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company, at their meeting held today, i.e., September 23, 2025, basis the recommendation of the Nomination and Remuneration Committee and subject to the approval of the shareholders of the Company, has approved modifications to the roles and responsibilities of the Executive Leadership, **effective April 1, 2026**. These changes are intended to align with the organisation's growth plans and to ensure a balanced focus on both short-term and long-term objectives.

- **Mr. Sucheth Rao Davuluri**, Whole-Time Director, currently designated as Vice Chairman & CEO, will be re-designated as **Executive Vice Chairman**. In his current role, Mr. Sucheth Davuluri has been driving a significant part of the day-to-day operations and has played a crucial role in helping the organisation become a strong, quality-focused API company, helping Neuland diversify from a generic API to a specialty API plus CDMO player. In this new role, Mr. Sucheth Davuluri will focus on strategic areas including long-term planning, enterprise risk management, stakeholder management, internal audit oversight, and CSR/philanthropic initiatives through Neuland Foundation.
- **Mr. Saharsh Rao Davuluri**, Whole-Time Director, currently designated as Vice Chairman & Managing Director, will be re-designated as **CEO & Managing Director**. In his current role, Mr. Saharsh Rao has helped build the CMS business elevating Neuland to a reputed CDMO. Mr. Saharsh Rao will assume responsibility for day-to-day operations, leveraging his experience in building the CMS business and understanding of client and market needs. This change will help the organization better fulfil the Company's commitments and maintain the trust of and goodwill with customers.

- A transition period shall commence with immediate effect and continue until March 31, 2026, to ensure a seamless transition of operational responsibilities. Upon completion of this period, effective April 1, 2026, the transition will be deemed complete and the changes in roles and responsibilities will become formal, subject to the approval of the shareholders.
- Both Mr. Sucheth Rao Davuluri and Mr. Saharsh Rao Davuluri will continue to report directly to the Executive Chairman, Dr. D. R. Rao.

The details as required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the above is enclosed as **Annexure A**.

This is for your information and records.

Thanking you,

Yours faithfully,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Annexure A

Details required under Regulation 30 of SEBI Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sl. No.	Particulars	Details	
1.	Name	Mr. D. Sucheth Rao	Mr. D. Saharsh Rao
2.	DIN	00108880	02753145
3.	Reason for change viz. appointment, resignation, removal, death or otherwise	The Board of Directors on the recommendation of the Nomination and Remuneration Committee, approved the re-designation of Mr. Sucheth Rao Davuluri, Whole-Time Director, currently designated as Vice Chairman & CEO, as Executive Vice Chairman, effective April 1, 2026, subject to the approval of the shareholders of the Company.	The Board of Directors on the recommendation of the Nomination and Remuneration Committee, approved the re-designation of Mr. Saharsh Rao Davuluri, Whole-Time Director, currently designated as Vice Chairman & Managing Director, as CEO & Managing Director, effective April 1, 2026, subject to the approval of the shareholders of the Company.
4.	Date of appointment and term of appointment	Not Applicable	
5.	Brief Profile	Not Applicable	
6.	Disclosure of relationships between directors	Mr. D. Sucheth Rao and Mr. D. Saharsh Rao are brothers; and sons of Dr. D. Rama Mohan Rao, Executive Chairman.	
7.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20th June 2018	Not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	